Biotech's IPO Tide Turning Amid M&A Surge on May 13, 2026 Alamar Biosciences IPOs Kailera Therapeutics M&A surge patent cliff +
Kailera CEO Confident Before Record-Breaking $625M Obesity Biotech IPO on April 17, 2026 Glucagon-Like Peptide 1 IPO Kailera Therapeutics methionine Obesity ribupatide Ron Renaud +
Kailera Therapeutics Files for Nasdaq IPO to Fund Obesity Drug Pipeline Licensed from China Partner on March 30, 2026 China Glucagon-Like Peptide 1 Hengrui IPO Kailera Therapeutics Nasdaq Obesity +